The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website.
- Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens
- In the two different dose regimens vaccine efficacy was 90% in one and 62% in the other
- Higher efficacy regimen used a halved first dose and standard second dose
- Early indication that vaccine could reduce virus transmission from an observed reduction in asymptomatic infections
- There were no hospitalised or severe cases in anyone who received the vaccine
- Large safety database from over 24,000 volunteers from clinical trials in the UK, Brazil and South Africa, with follow up since April
- Crucially, vaccine can be easily administered in existing healthcare systems, stored at ‘fridge temperature’ (2-8 °C) and distributed using existing logistics
- Large scale manufacturing ongoing in over 10 countries to support equitable global access
Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said:
‘These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regimen is used, more people could be vaccinated with planned vaccine supply. Today’s announcement is only possible thanks to the many volunteers in our trial, and the hard working and talented team of researchers based around the world.’
Professor Sarah Gilbert, Professor of Vaccinology at the University of Oxford, said:
‘The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by SARS-CoV-2. We will continue to work to provide the detailed information to regulators. It has been a privilege to be part of this multi-national effort which will reap benefits for the whole world.’
Top Image Credit: John Cairns
Post by Amanda Scott, NA CEO. Follow her on twitter @tantriclens
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News
Omicron subvariant BA.2 replicates faster in brain cells than other strains, study finds
Omicron subvariant BA.2 – which was dominant worldwide early this year, including in Hong Kong – replicates more swiftly than other strains and causes faster programmed cell death in human brains, a new study has found. [...]
Seeding the oceans with iron-rich fertilizer nanoparticles to store excess carbon dioxide
The urgent need to remove excess carbon dioxide from Earth’s environment could include enlisting some of our planet’s smallest inhabitants, according to an international research team led by Michael Hochella of the Department of [...]
Temporary graphene ‘tattoos’ that measure blood pressure
Blood pressure is a key vital sign that provides insight into our cardiovascular health. But blood pressure is typically measured only a few times per year by a clinician—and these measurements might not always [...]
Next Covid-19 Strain May be More Dangerous, Lab Study Shows
A South African laboratory study using Covid-19 samples from an immunosupressed individual over six months showed that the virus evolved to become more pathogenic, indicating that a new variant could cause worse illness than [...]
The Fast-Spreading New COVID-19 Subvariant XBB Is Part of a ‘New Class’ of Omicron
For the past several months, Omicron subvariants BA.4 and BA.5 have dominated COVID-19 cases in the U.S. But now, there’s a class of new COVID subvariants on the rise and one in particular is getting plenty of [...]
Overcoming challenges in the delivery of nucleic acid therapeutics
Nucleic acid therapies involving DNA or RNA have significant potential to treat genetic disorders, infectious diseases, and cancer; however, research suggests that less than 1% of injected nucleic acid doses reach target cells in [...]
FDA approves $3.5 million treatment for hemophilia, now the most expensive drug in the world
The US Food and Drug Administration on Tuesday approved Hemgenix, a new drug to treat hemophilia. Manufacturer CSL Behring set the price at $3.5 million per treatment, making it the most expensive drug [...]
Wireless smart bandage promotes faster closure of wounds, enhances skin recovery
Some wounds just won’t heal. Infections, diseases like diabetes, and suppressed immune systems often stack up to slow healing. Chronic wounds can last months and lead to anxiety and depression. In the worst cases, [...]
Using Nanofibers to Guide the Development of Novel Biomaterials
Over the years, researchers have tried hard to comprehend topographic signals that promote cell mechanical sensitive responses. The extracellular matrix (ECM) provides a complex cellular microenvironment that controls cellular behavior. Nevertheless, only a few [...]
Measles now an imminent global threat due to pandemic, say WHO and CDC
There is now an imminent threat of measles spreading in various regions globally, as COVID-19 led to a steady decline in vaccination coverage and weakened surveillance of the disease, the World Health Organization (WHO) [...]
Covid-19: Brain scans show new evidence of what could be causing long Covid
In a recent study, it was shown that people with long Covid have had physical changes to their brains several months after experiencing the initial infection. The study included MRIs of patients who continued [...]
Western University is building Canada’s secret weapon against the next pandemic
Western University in London, Ont., is building a unique research lab to study humanity's greatest viral threats — a secret weapon, if you will, one that it's expected would put Canada and the world in a better position if [...]
Cancer patients test world’s first ‘computer-designed’ antibodies, made in Israel
Cancer patients are testing a medicine made of antibodies that were designed from scratch on a computer in Israel and whose inventor has “programmed” them to “decide” whether cells surrounding tumors are bad or good. [...]
Corrosion-Resistant Superhydrophobic Graphene-Based Coatings on Copper Substrate
In an article published in the journal Scientific Reports, researchers presented the potentiostatic deposition used to electrodeposit nickel (Ni) and nickel-graphene (Ni-G) films on copper substrates. Myristic acid (MA) was employed to alter the plane of the [...]
A chip to replace animal testing
New drugs made from nanoparticles that can easily penetrate any interface within our bodies are a great hope in medicine. For such hopefuls to reach the market, their safety must be ensured. In this [...]
Researchers develop new, heat-efficient nanoparticles for treating cancer
Oregon State University scientists have invented a way to make magnetic nanoparticles that get hotter than any previous nanoparticle, improving their cancer fighting ability. Faculty from the OSU College of Pharmacy spearheaded a collaboration [...]
